JP2006522827A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006522827A5 JP2006522827A5 JP2006509898A JP2006509898A JP2006522827A5 JP 2006522827 A5 JP2006522827 A5 JP 2006522827A5 JP 2006509898 A JP2006509898 A JP 2006509898A JP 2006509898 A JP2006509898 A JP 2006509898A JP 2006522827 A5 JP2006522827 A5 JP 2006522827A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- compound according
- alkyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 49
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 16
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 16
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000002837 carbocyclic group Chemical group 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 8
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims description 5
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 5
- -1 acyclic amine Chemical class 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- CEPCPXLLFXPZGW-UHFFFAOYSA-N 2,4-difluoroaniline Chemical compound NC1=CC=C(F)C=C1F CEPCPXLLFXPZGW-UHFFFAOYSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical group NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 8
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 6
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 5
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 4
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- AVGHIQUXSVAJBC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.1]heptane Chemical compound C1C2CCN1NC2 AVGHIQUXSVAJBC-UHFFFAOYSA-N 0.000 claims 3
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 claims 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 3
- KSCPLKVBWDOSAI-UHFFFAOYSA-N 2,3,4,4a,5,6,7,7a-octahydro-1h-pyrrolo[3,4-b]pyridine Chemical compound N1CCCC2CNCC21 KSCPLKVBWDOSAI-UHFFFAOYSA-N 0.000 claims 3
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims 3
- UKHJNJFJCGBKSF-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.1]heptane Chemical compound C1NC2CNC1C2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 claims 3
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 claims 3
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 3
- HXJUTPCZVOIRIF-UHFFFAOYSA-N Tetrahydrothiophene-1,1-dioxide, Natural products O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Chemical group N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 3
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 claims 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 3
- 229930192474 thiophene Natural products 0.000 claims 3
- 150000003852 triazoles Chemical class 0.000 claims 3
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 claims 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical compound C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 claims 1
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 claims 1
- GDALETGZDYOOGB-UHFFFAOYSA-N Acridone Natural products C1=C(O)C=C2N(C)C3=CC=CC=C3C(=O)C2=C1O GDALETGZDYOOGB-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 claims 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000004305 biphenyl Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical group N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical group N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Chemical group 0.000 claims 1
- 125000004946 alkenylalkyl group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46127103P | 2003-04-07 | 2003-04-07 | |
| US46317103P | 2003-04-15 | 2003-04-15 | |
| US51953503P | 2003-11-12 | 2003-11-12 | |
| US53272703P | 2003-12-23 | 2003-12-23 | |
| PCT/US2004/011108 WO2004091504A2 (en) | 2003-04-07 | 2004-04-07 | Substituted quinobenzoxazine analogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006522827A JP2006522827A (ja) | 2006-10-05 |
| JP2006522827A5 true JP2006522827A5 (enExample) | 2007-05-31 |
Family
ID=33304104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509898A Pending JP2006522827A (ja) | 2003-04-07 | 2004-04-07 | 置換キノベンゾオキサジン類似体 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US7141565B1 (enExample) |
| EP (1) | EP1610759A4 (enExample) |
| JP (1) | JP2006522827A (enExample) |
| KR (1) | KR100944600B1 (enExample) |
| AU (1) | AU2004229489B2 (enExample) |
| BR (1) | BRPI0409105A (enExample) |
| CA (1) | CA2521810A1 (enExample) |
| MX (1) | MXPA05010776A (enExample) |
| NO (1) | NO20054669L (enExample) |
| NZ (1) | NZ543006A (enExample) |
| WO (1) | WO2004091504A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507727B2 (en) * | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
| US7354916B2 (en) * | 2003-04-07 | 2008-04-08 | Cylene Pharmaceuticals | Substituted quinobenzoxazine analogs |
| WO2004091504A2 (en) * | 2003-04-07 | 2004-10-28 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs |
| EP1673478A4 (en) * | 2003-10-14 | 2007-08-22 | Cylene Pharmaceuticals Inc | COMPETITION TEST TO IDENTIFY QUADRUPLEX NUCLEIC ACID MODULATORS |
| DE102004035203A1 (de) * | 2004-07-21 | 2006-02-16 | Bayer Healthcare Ag | Substituierte Chinolone |
| US7652134B2 (en) * | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
| EP1802306A2 (en) * | 2004-09-17 | 2007-07-04 | Cylene Pharmaceuticals, Inc. | Quinolone analog as cell proliferation inhibitors |
| EP1874731A4 (en) * | 2005-04-15 | 2009-08-05 | Cylene Pharmaceuticals Inc | CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION |
| US7610985B2 (en) * | 2005-05-18 | 2009-11-03 | Kanzaki Kokyukoki Mfg. Co., Ltd. | HST unit |
| DE102006005861A1 (de) | 2006-02-09 | 2007-08-23 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone III |
| WO2007137000A2 (en) * | 2006-05-16 | 2007-11-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
| US20070293485A1 (en) * | 2006-06-03 | 2007-12-20 | John Lim | Drug administration methods |
| US8410070B2 (en) * | 2008-09-12 | 2013-04-02 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death |
| TW201120037A (en) | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
| US9730609B2 (en) * | 2011-12-15 | 2017-08-15 | Siemens Healthcare Gmbh | Method and system for aortic valve calcification evaluation |
| JP6249436B2 (ja) * | 2012-08-31 | 2017-12-20 | 国立大学法人東京農工大学 | 四重らせんｄｎａ検出プローブ及びそれを用いた四重らせん構造の検出方法 |
| CN106459068B (zh) | 2014-05-09 | 2019-01-22 | 皮梅拉股份有限公司 | 新组合物、用途和制备它们的方法 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| CN110709400A (zh) | 2017-03-28 | 2020-01-17 | 皮梅拉股份有限公司 | Pol1抑制剂的新型晶体形式 |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| CN114716373B (zh) * | 2022-04-14 | 2023-01-10 | 内蒙古源宏精细化工有限公司 | 一种加替沙星环合酯的制备方法 |
| CN116023263A (zh) * | 2022-11-17 | 2023-04-28 | 苏州汉德创宏生化科技有限公司 | 一种中间体3-(3,5-二氯苯基)-3-氧代丙酸乙酯的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4533663A (en) | 1984-04-26 | 1985-08-06 | Abbott Laboratories | Quino-benzothiazine antibacterial compounds |
| US4607032A (en) | 1984-04-26 | 1986-08-19 | Abbott Laboratories | Quino-benoxazine antibacterial compounds |
| DE3578424D1 (de) * | 1984-04-26 | 1990-08-02 | Abbott Lab | Quino-benzothiazin-antibakterielle verbindungen. |
| JPH0665676B2 (ja) * | 1984-04-26 | 1994-08-24 | アボツト ラボラトリーズ | キノリン‐ベノキサジン抗菌性化合物 |
| US4528285A (en) * | 1984-04-26 | 1985-07-09 | Abbott Laboratories | Methylenedioxy quino-benzothiazine derivatives |
| DE3600891A1 (de) * | 1986-01-15 | 1987-07-16 | Bayer Ag | 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| JPH0240379A (ja) | 1988-07-28 | 1990-02-09 | Wakunaga Pharmaceut Co Ltd | 新規キノロン誘導体 |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| IE912902A1 (en) * | 1990-08-24 | 1992-02-26 | Abbott Lab | Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents |
| US5318965A (en) * | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| US5225418A (en) | 1991-12-17 | 1993-07-06 | Du Pont Merck Pharmaceutical Company | 5H-(1,2)benzisothiazolo[2,3-a]quinoline-5-ones and analogs as antiinflammatory agents |
| CA2253710A1 (en) | 1996-04-25 | 1997-10-30 | Spectrametrix Inc. | Analyte assay using particulate labels |
| US5992478A (en) * | 1996-07-08 | 1999-11-30 | The Boc Group, Inc. | Method and apparatus for filling containers with gas mixtures |
| US6528517B1 (en) | 1998-02-04 | 2003-03-04 | Board Of Regents, The University Of Texas System | Synthesis of quinobenzoxazine analogues with topoisomerase II and quadruplex interactions for use as antineoplastic agents |
| EP1175217B8 (en) * | 1999-05-07 | 2009-03-18 | Wockhardt Limited | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents |
| US6750224B1 (en) | 1999-05-07 | 2004-06-15 | Wockhardt Limited | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment |
| US20020049223A1 (en) | 1999-11-05 | 2002-04-25 | Elmore Steven W. | Quinoline and naphthyridine carboxylic acid antibacterials |
| ES2227232T3 (es) * | 2000-07-12 | 2005-04-01 | PHARMACIA & UPJOHN COMPANY | Oxazinoquinolonas utiles para el tratamiento de infecciones virales. |
| AU3089102A (en) | 2000-12-14 | 2002-06-24 | Procter & Gamble | Antimicrobial quinolones |
| US6818654B2 (en) | 2002-03-12 | 2004-11-16 | Abbott Laboratories | Antibacterial compounds |
| US8163769B2 (en) | 2002-03-12 | 2012-04-24 | Abbott Laboratories | Antibacterial compounds |
| US6900224B2 (en) | 2002-07-31 | 2005-05-31 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| WO2004091504A2 (en) | 2003-04-07 | 2004-10-28 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs |
| US7354916B2 (en) * | 2003-04-07 | 2008-04-08 | Cylene Pharmaceuticals | Substituted quinobenzoxazine analogs |
| EP1610795A4 (en) | 2003-04-07 | 2007-10-24 | Cylene Pharmaceuticals Inc | SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE HETEROCYCLIC ANALOGUES |
| CN100390771C (zh) * | 2003-05-07 | 2008-05-28 | 皇家飞利浦电子股份有限公司 | 用于发送数据的处理系统和方法 |
| US7196200B2 (en) | 2004-01-21 | 2007-03-27 | Abbott Laboratories | Antibacterial compounds |
| JP4517731B2 (ja) * | 2004-05-31 | 2010-08-04 | 日産自動車株式会社 | 内燃機関のコネクティングロッド設計方法 |
-
2004
- 2004-04-07 WO PCT/US2004/011108 patent/WO2004091504A2/en not_active Ceased
- 2004-04-07 JP JP2006509898A patent/JP2006522827A/ja active Pending
- 2004-04-07 EP EP04759406A patent/EP1610759A4/en not_active Withdrawn
- 2004-04-07 BR BRPI0409105-1A patent/BRPI0409105A/pt not_active IP Right Cessation
- 2004-04-07 MX MXPA05010776A patent/MXPA05010776A/es active IP Right Grant
- 2004-04-07 CA CA002521810A patent/CA2521810A1/en not_active Abandoned
- 2004-04-07 US US10/821,243 patent/US7141565B1/en not_active Expired - Fee Related
- 2004-04-07 NZ NZ543006A patent/NZ543006A/en not_active IP Right Cessation
- 2004-04-07 KR KR20057019057A patent/KR100944600B1/ko not_active Expired - Fee Related
- 2004-04-07 AU AU2004229489A patent/AU2004229489B2/en not_active Ceased
-
2005
- 2005-10-11 NO NO20054669A patent/NO20054669L/no not_active Application Discontinuation
-
2006
- 2006-03-28 US US11/390,810 patent/US7326702B2/en not_active Expired - Fee Related
- 2006-05-10 US US11/431,602 patent/US7381720B2/en not_active Expired - Fee Related
-
2007
- 2007-03-30 US US11/694,682 patent/US20120122804A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/013,961 patent/US7612063B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006522827A5 (enExample) | ||
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| US6245759B1 (en) | Tyrosine kinase inhibitors | |
| ES2235970T3 (es) | Inhibidores de tirosina quinasa. | |
| RU2012119488A (ru) | Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором | |
| WO2006113509B1 (en) | Quinobenzoxazine analogs and methods of using thereof | |
| KR20090050094A (ko) | 세린-트레오닌 단백질 키나제 및 ｐａｒｐ 조절제 | |
| NZ601847A (en) | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor | |
| PE20120629A1 (es) | Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina | |
| JP2016506419A5 (enExample) | ||
| AR086528A2 (es) | Combinacion farmaceutica | |
| JP2018501315A5 (enExample) | ||
| RU2011116160A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и y-глутамиламиногруппой и содержащие их противогрибковые средства | |
| AU2005289644A1 (en) | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases | |
| JP2012502067A5 (enExample) | ||
| JP2018525375A5 (enExample) | ||
| AR074814A1 (es) | Pirimidinas sustituidas como antagonistas del receptor ccr2 y usos de las mismas en medicamentos. | |
| JP2015509956A5 (enExample) | ||
| WO2014074926A1 (en) | Therapeutic hydroxyquinolones | |
| JP2013508412A5 (enExample) | ||
| KR102135230B1 (ko) | 세펨 화합물, 그의 제조 및 용도 | |
| JP2008513485A5 (enExample) | ||
| AU2016356884A1 (en) | Novel compounds as inhibitors of dna methyltransferases | |
| JP2010512359A (ja) | 抗癌剤としてのｃ１２−ｃ１３位で修飾されたエポチロン類似体 | |
| RU2006138606A (ru) | Ингибиторы киназы |